Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo—a Meta-analysis of Individual Data From Controlled Trials-Reference-Cited by-同舟云学术

Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo—a Meta-analysis of Individual Data From Controlled Trials

Published:2018-08 Issue:2 Volume:155 Page:458-468.e8
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Louvet Alexandre,Thursz Mark R.^ORCID,Kim Dong Joon,Labreuche Julien,Atkinson Stephen R.,Sidhu Sandeep Singh,O’Grady John G.,Akriviadis Evangelos,Sinakos Emmanouil^ORCID,Carithers Robert L.^ORCID,Ramond Marie-José,Maddrey Willis C.,Morgan Timothy R.,Duhamel Alain^ORCID,Mathurin Philippe

Funder

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference37 articles.

1. Alcoholic liver disease;O'Shea;Hepatology,2010

2. EASL clinical practical guidelines: management of alcoholic liver disease;J Hepatol,2012

3. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial;Akriviadis;Gastroenterology,2000

4. [Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis];Daures;Gastroenterol Clin Biol,1991

5. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials;Imperiale;Ann Intern Med,1990

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The landscape of inpatient admissions for alcoholic hepatitis in the era of early liver transplantation;Annals of Hepatology;2024-03

2. Alcohol-associated liver disease;Journal of Clinical Investigation;2024-02-01

3. Granulocyte-monocyte/macrophage apheresis for steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis: A pilot study;Hepatology Communications;2024-01-29

4. Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis;Hepatology Communications;2023-12

5. Past, Present, and Future Therapies for Alcohol-associated Hepatitis;Clinical Therapeutics;2023-12